Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC
Status:
Terminated
Trial end date:
2021-06-11
Target enrollment:
Participant gender:
Summary
CONTESSA 2 is a multinational, multicenter, Phase 2 study of tesetaxel in patients with HER2
negative, HR positive, locally advanced or metastatic breast cancer (LA/MBC) not previously
treated with a taxane. The primary objective of the study is to establish the efficacy of
tesetaxel plus a reduced dose of capecitabine based on objective response rate (ORR) as
assessed by an Independent Radiologic Review Committee (IRC). 152 patients were enrolled.